Workflow
Shareholder litigation
icon
搜索文档
CHTR INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Charter Communications, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
Globenewswire· 2025-09-28 17:40
SAN DIEGO, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Charter Communications, Inc. (NASDAQ: CHTR) securities, including purchasers of call options or sellers of put options between July 26, 2024 and July 24, 2025, all dates inclusive (the “Class Period”), have until Tuesday, October 14, 2025 to seek appointment as lead plaintiff of the Charter Communications class action lawsuit. Captioned Sandoval v. Charter Communications, Inc., No. 25-cv- ...
Kuehn Law Encourages Investors of Hims & Hers Health, Inc. to Contact Law Firm
Prnewswire· 2025-09-24 18:13
Accessibility StatementSkip Navigation NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Hims & Hers Health, Inc.  (NYSE: HIMS) breached their fiduciary duties to shareholders. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED According to a federal securities lawsuit, Insiders at Hims & Hers Health caused the c ...
Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm
Prnewswire· 2025-09-24 18:10
Accessibility StatementSkip Navigation NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Sarepta Therapeutics caused the company to misrepresent or fail to disclose that (i) ELEVIDYS posed significant safety risks to patients: (ii) ELEVIDYS trial regimes and pro ...
Shareholder Alert: The Ademi Firm investigates whether Semler Scientific Inc. is obtaining a Fair Price for its Public Shareholders
Prnewswire· 2025-09-22 17:40
The transaction agreement unreasonably limits competing transactions for Semler Scientific by imposing a significant penalty if Semler Scientific accepts a competing bid. We are investigating the conduct of the Semler Scientific board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. Accessibility StatementSkip Navigation MILWAUKEE, Sept. 22, 2025 /PRNewswire/ -- The Ademi Firm is investigating Semler Scientific (Nasdaq: SMLR) for possible breaches of fiduciary duty a ...
Shareholder Alert: The Ademi Firm investigates whether Metsera Inc. is obtaining a Fair Price for its Public Shareholders
Prnewswire· 2025-09-22 14:00
Accessibility StatementSkip Navigation MILWAUKEE, Sept. 22, 2025 /PRNewswire/ -- The Ademi Firm is investigating Metsera (Nasdaq: MTSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Metsera will receive $47.50 per share in a transaction with an enterprise ...
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Prnewswire· 2025-09-19 17:35
公司业务模式与收入构成 - 公司被指控将自己标榜为人工智能企业 但缺乏从人工智能解决方案产生重大收入的历史[1] - 公司大部分收入来自收购活动、基因组测试及数据许可协议 而非核心人工智能业务[1] - 公司强调与长期客户阿斯利康的合作关系 并宣布通过公司与阿斯利康及Pathos AI的合资企业扩大合作[1] 市场扩张与合作伙伴关系 - 公司宣布与软银成立合资企业 以此作为进入日本市场并推动收入增长的方式[1] - 公司声称被收购目标Ambry Genetics具有高收入潜力 并强调其与医疗保健提供商的稳固关系推动了加速增长[1] 信息披露与法律调查 - 公司内部人士多次声称其与生命科学公司的数据许可协议合同价值和质量安全且不断扩大[1] - 股东诉讼律师事务所正在调查公司某些高管及董事是否违反了对股东的信义义务[1]
Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm
Prnewswire· 2025-09-15 17:08
公司调查 - 股东诉讼律师事务所Kuehn Law正在调查Twist Bioscience Corporation高管和董事是否违反了对股东的信义义务 [1] - 调查涉及公司高管被指控通过会计欺诈和使用不可持续的定价来夸大公司真实财务状况和前景 [1] - 诉讼指控公司内部人士夸大了其合成DNA制造技术的商业可行性 [1] 指控内容 - 联邦证券诉讼指控Twist Bioscience内部人士导致公司做出重大虚假和/或误导性陈述 [1] - 公司被指控未能披露有关其业务和运营的重大不利事实 [1] - 具体指控包括通过会计欺诈和不可持续的定价手段来夸大公司真实财务状况 [1] 股东参与 - 律师事务所鼓励在2019年12月13日前购买TWST股票的股东联系该律所 [2] - 律所承担所有案件成本且不向投资者客户收费 [2] - 股东被建议立即联系律所以维护自身权利 [2] 律所业务 - Kuehn Law同时也在调查Ultra Clean Holdings Inc高管和董事的类似问题 [4] - 该律所还在调查DexCom Inc高管和董事是否违反信义义务 [5] - 律所业务模式专注于股东衍生诉讼领域 [3]
DOW INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Dow Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Globenewswire· 2025-09-15 15:12
SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Dow Inc. (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, both dates inclusive (the “Class Period”), have until Tuesday, October 28, 2025 to seek appointment as lead plaintiff of the Dow class action lawsuit. Captioned Sarti v. Dow Inc., No. 25-cv-12744 (E.D. Mich.), the Dow class action lawsuit charges Dow, The Dow Chemical Company, a Dow subsidiary, and ...
SNAP INVESTOR NOTICE: Snap Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Prnewswire· 2025-09-13 02:20
集体诉讼案件 - 律师事务所Robbins Geller宣布Snap集体诉讼的潜在首席原告申请截止日期为2025年10月20日 案件编号为Abdul-Hameed v Snap Inc No 25-cv-07844 [1] - 诉讼指控Snap及其高管违反1934年证券交易法 涉及2025年4月29日至8月5日期间购买公司证券的投资者 [1] 指控内容 - 被告被指控制造虚假信息 声称拥有可靠的广告收入预期和增长信息 同时强调宏观经济不稳定性 [3] - 实际上Snap的广告增长和盈利潜力报告过于依赖执行能力 且已出现重大执行错误 但被告却归咎于宏观经济条件 [3] - 2025年8月5日披露的第二季度财报显示广告收入显著减速 部分原因是竞价系统变更导致广告活动以大幅降低价格成交 [4] - 财报公布后Snap股价下跌超过17% [4] 公司业务背景 - Snap是一家科技公司 主营业务涉及广告技术领域 [2] 律师事务所信息 - Robbins Geller在证券欺诈诉讼领域排名第一 过去五年中有四年在ISS证券集体诉讼服务排名中位列首位 [6] - 2024年该律所为投资者追回超过25亿美元赔偿 金额超过其他五家律所总和 [6] - 曾办理历史上最大证券集体诉讼案 在安然公司案件中追回72亿美元赔偿 [6]
CHTR INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Charter Communications, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Prnewswire· 2025-08-30 01:00
核心观点 - 针对Charter Communications的集体诉讼指控公司在2024年7月26日至2025年7月24日期间就联邦通信委员会 Affordable Connectivity Program (ACP) 终止的影响做出虚假和/或误导性陈述 未能披露该计划终止对互联网客户流失和收入的持续负面影响 且公司缺乏有效应对策略 导致股价单日下跌超过18% [1][3][4] 公司业务与运营 - Charter Communications是一家宽带连接和有线电视运营商 为住宅和商业客户提供服务 [2] - 公司2025年第二季度EBITDA为57亿美元 同比增长0.5% 但互联网客户减少11.7万户 其中约5万户断网与2024年第二季度ACP终止直接相关 [4] - 诉讼指控公司未能有效管理ACP终止带来的重大影响 运营策略存在执行缺陷 无法补偿计划结束造成的损失 [3] 财务表现与市场反应 - 2025年7月25日发布Q2财报后 公司股价下跌超过18% 市场对客户流失和增长前景表示担忧 [4] - 公司关于业务计划和盈利增长的声明被指控缺乏合理基础 未如实反映ACP终止带来的持续风险 [3] 法律程序相关 - 集体诉讼涉及1934年证券交易法违规指控 由纽约南区法院受理 案件编号25-cv-06747 [1] - 潜在原告需在2025年10月14日前申请成为首席原告 涵盖期间内购买证券、看涨期权或出售看跌期权的投资者均符合资格 [1][5]